Drägerwerk AG & Co. KGaA (pref) - Asset Resilience Ratio
Drägerwerk AG & Co. KGaA (pref) (DRW3) has an Asset Resilience Ratio of 0.86% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how Drägerwerk AG & Co. KGaA (pref)'s Asset Resilience Ratio has changed over time. Check Drägerwerk AG & Co. KGaA (pref) (DRW3) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Drägerwerk AG & Co. KGaA (pref)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Drägerwerk AG & Co. KGaA (pref) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €27.34 Million | 0.86% |
| Total Liquid Assets | €27.34 Million | 0.86% |
Asset Resilience Insights
- Limited Liquidity: Drägerwerk AG & Co. KGaA (pref) maintains only 0.86% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Drägerwerk AG & Co. KGaA (pref) Industry Peers by Asset Resilience Ratio
Compare Drägerwerk AG & Co. KGaA (pref)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Edwards Lifesciences Corp
NYSE:EW |
Medical Devices | 9.20% |
|
DexCom Inc
NASDAQ:DXCM |
Medical Devices | 19.55% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212 |
Medical Devices | 6.09% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Corentec Co Ltd
KQ:104540 |
Medical Devices | 2.80% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Annual Asset Resilience Ratio for Drägerwerk AG & Co. KGaA (pref) (2013–2025)
The table below shows the annual Asset Resilience Ratio data for Drägerwerk AG & Co. KGaA (pref).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.40% | €12.74 Million ≈ $14.89 Million |
€3.16 Billion ≈ $3.70 Billion |
-0.40pp |
| 2024-12-31 | 0.80% | €24.72 Million ≈ $28.90 Million |
€3.09 Billion ≈ $3.62 Billion |
+0.64pp |
| 2023-12-31 | 0.16% | €4.86 Million ≈ $5.69 Million |
€3.09 Billion ≈ $3.62 Billion |
+0.02pp |
| 2022-12-31 | 0.14% | €4.21 Million ≈ $4.92 Million |
€3.11 Billion ≈ $3.63 Billion |
-4.04pp |
| 2021-12-31 | 4.18% | €132.72 Million ≈ $155.16 Million |
€3.18 Billion ≈ $3.72 Billion |
-0.27pp |
| 2020-12-31 | 4.44% | €146.85 Million ≈ $171.68 Million |
€3.31 Billion ≈ $3.87 Billion |
+4.32pp |
| 2019-12-31 | 0.12% | €3.07 Million ≈ $3.59 Million |
€2.57 Billion ≈ $3.01 Billion |
+0.06pp |
| 2018-12-31 | 0.06% | €1.44 Million ≈ $1.68 Million |
€2.41 Billion ≈ $2.82 Billion |
+0.04pp |
| 2017-12-31 | 0.02% | €555.00K ≈ $648.85K |
€2.35 Billion ≈ $2.75 Billion |
0.00pp |
| 2016-12-31 | 0.03% | €584.00K ≈ $682.76K |
€2.31 Billion ≈ $2.70 Billion |
-0.11pp |
| 2015-12-31 | 0.14% | €3.15 Million ≈ $3.68 Million |
€2.31 Billion ≈ $2.70 Billion |
+0.07pp |
| 2014-12-31 | 0.06% | €1.43 Million ≈ $1.67 Million |
€2.23 Billion ≈ $2.61 Billion |
0.00pp |
| 2013-12-31 | 0.07% | €1.39 Million ≈ $1.62 Million |
€2.07 Billion ≈ $2.41 Billion |
-- |
About Drägerwerk AG & Co. KGaA (pref)
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, devices, and services for the medical division, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas m… Read more